Tailored to hospitals and patients in China, the Joy Series provides a range of ultrasound diagnostic and clinical solutions tailored to specific diseases and hospital needs at different levels.
In March 2022, Philips announced that the new national ultrasound product "Yuexiang Series" developed and produced by Philips (Suzhou) Medical Imaging Base and global resources was approved for listing.
As a high-end ultrasound product line, this product line contains a total of 5 products, tailored for Chinese hospitals and patients, which can meet the comprehensive clinical needs, especially on the basis of systemic application ultrasound, bringing a wealth of cardiovascular, oncology and maternal and child care and other clinical solutions.
Increasing the innovation of Philips Ultrasonic China R&D team and launching the Philips Enjoyment series customized for Chinese hospitals and patients also marks the continuous acceleration of Philips localization process. It is understood that Philips' ultrasonic probe research and development team in Shanghai is responsible for nearly one-third of the world's ultrasonic probe research and development tasks; the ultrasonic products required by the Chinese market are expected to achieve 100% Chinese manufacturing and production in 2022.
Deeply rooted in the Chinese market for more than 30 years, "in China, for China" is Philips' long-term commitment to the Chinese market.
"Our goal is to make full use of the abundant senior talents in the Chinese market and China's supply chain advantages, always based on local needs, accelerate efficiency, optimize costs, develop and produce local tailor-made solutions to serve China and the world." Chen Shengyu, senior vice president of Philips Greater China and general manager of the precision diagnostic business group, said.
Senior Vice President, Philips Greater China,
Mr. Chen Shengyu, General Manager of Precision Diagnostic Business Group
Why is the Joy Series leading the ultrasound market?
As a pioneer in the medical imaging industry, Philips leads the ultrasound market with two major advantages: one is the continuous upgrading of high-end imaging equipment, and the other is to innovate and apply digital technology to data and image processing to support clinical diagnostic decisions, improve hospital processes, improve efficiency and quality control.
Philips was the first company in the industry to develop and produce pure wave single crystal probes with pure wave single crystal probe solutions for the entire clinical field. The new pure wave single crystal replaces the ordinary probe application material, which is superior in bandwidth and sensitivity, has stronger penetration and higher resolution, can help obese patients obtain better images, bring the most intuitive clinical experience for doctors, and effectively reduce missed diagnosis and misdiagnosis.
Some probes are shown
Not only accurate, but also comprehensive. It is understood that the Yuexiang series is equipped with a pure wave single crystal probe in the whole clinical field, which can cover clinical applications from the conventional abdomen, superficial surface, heart, pediatrics, transesophagus, vascular, obstetrics and gynecology, intervention, reproduction and other aspects. At the same time, most of the probes in the Yuexiang series can be used with other Philips models, which can greatly improve the turnover rate of hospital departments and avoid idle probes.
Provide diagnosis and treatment solutions for the needs of ultrasound markets
The Philips Enjoy series includes 5 products that provide a wealth of clinical solutions for the pain points and needs of the Chinese ultrasound market, including cardiovascular, oncology and maternal and child care.
▌ Leading Cardiovascular Solutions:
Contribute to the achievement of national health strategic goals
According to the "China Cardiovascular Health and Disease Report 2020" released by the National Center for Cardiovascular Diseases in August 2020, the number of cardiovascular patients in mainland China is 330 million, and the mortality rate of cardiovascular diseases accounts for the first cause of death among urban and rural residents on the mainland. Philips ultrasound has a wide range of applications in the cardiovascular field and can meet the comprehensive clinical needs. The Joy Series supports the linkage of pure wave and matrix technology, from transthoracic pure crystal images, to high frame frequency transesophageal three-dimensional, from single field of view to real-time same-plane dual-field observation, from two-dimensional to three-dimensional quantitative, fully demonstrating Philips ultrasound's leading edge in the field of heart.
▌Precision Oncology Solutions:
Help tumor prevention and treatment sinking grass-roots hospitals
In 2019, the National Cancer Center released the 2015 malignant tumor epidemic analysis report annual record, the incidence of malignant tumors in mainland China increased by 3.9% per year, and the mortality rate of malignant tumors increased by 2.5% per year. Especially in primary hospitals, it undertakes the screening of most tumor diseases and the long-term follow-up and follow-up after anti-tumor treatment. Aiming at the clinical pain points of Chinese hospitals, the pure wave single crystal probe in the whole clinical field configured by the Yuexiang series has better image performance and can accurately find the lesions and difficult points of difficult cases. At the same time, ultrasound-guided interventional diagnosis and treatment is becoming a clinical hotspot, and the Yuexiang series can help doctors improve surgical planning in multimodal combined applications, reduce the risk of interventional operations, and improve surgical safety and success rate.
▌Comprehensive Obstetric Screening Solution:
Help prevent and control birth defects and protect the health of mothers and babies
Since the country opened up the two-child policy, the number of newborns has increased year by year. Ultrasonography is the most irreplaceable and noninvasive imaging technique for the fetus and can help doctors screen for birth defects more accurately. In particular, the incidence of fetal heart disease has always been the top of the list of birth defects in the past decade, with an incidence rate of 8‰-12‰. The Yuexiang series can provide patients with gynecological examination, pelvic floor examination, prospective early and middle pregnancy system screening, patients with difficulty in middle and late pregnancy, perinatal maternal-fetal disease, and comprehensive ultrasound solutions for newborns, fully meeting the comprehensive clinical needs for obstetrics and gynecology ultrasound.
Tailor-made for Chinese doctors and patients,
Philips ultrasound localization "full firepower"
In recent years, with the deepening of aging, the increase in the incidence of diseases, the opening of the two- and three-child policies, the small peak of fertility, and the extension and segmentation of ultrasound medicine in clinical applications, China's ultrasound medical imaging equipment market has maintained a stable development trend. According to forecasts, the market size of the medical imaging equipment industry in mainland China will increase from 96.7 billion yuan in 2021 to 129.1 billion yuan in 2025, with an average annual compound growth rate of 7.5%.
With the gradual improvement of the mainland medical system, the demand for medical imaging equipment is also increasing, and hospitals at all levels have also produced different needs for ultrasound equipment, which also puts forward higher requirements for ultrasound product developers - Philips Yuexiang series came into being, and five series of products can meet the overall clinical needs of Chinese hospitals and patients.
The Joy Series is also the first step in the localization of Philips ultrasound, marking the acceleration of Philips localization process.
"We use global resources to empower local innovation and local innovation in China. Comprehensive layout and strong acceleration of R&D, manufacturing and production in the Chinese market. Chen Shengyu said that Philips is deploying three innovation centers in Suzhou, Shenzhen and Shanghai, focusing on the localization of systems, products and software. The Precision Diagnostics business group will also significantly accelerate the pace of local innovation with the power of the innovation center, and plans to further enrich the localization product portfolio in the next one to three years, covering the entire production line in all business areas, including high-end products.
Philips will always adhere to the principle of "In China, for China", provide solutions centered on Chinese hospitals and patients, improve the level and level of scientific research, and realize the vision of health care. "In the future, the three innovation centers will not only serve China and innovate for China, but also supply these innovative solutions and services to the world." Chen Shengyu said.
*This article is only used to provide scientific information to healthcare professionals and does not represent the position of the Platform
![Gao Fu et al. disclosed the clinical results of protein subunit NEWCC vaccine Phase 3: long-term protection 75.7%[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)